Shopping Cart
- Remove All
Your shopping cart is currently empty
PCSK9-IN-10
🥰Excellent
Catalog No. T72025Cas No. 368434-98-4
PCSK9-IN-10, a potent and orally active inhibitor of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9), exhibits a half-maximal inhibitory concentration (IC50) of 6.4 µM. By enhancing the expression of Low-Density Lipoprotein Receptor (LDLR) protein and reducing PCSK9 expression, PCSK9-IN-10 effectively decreases atherosclerosis progression. This compound holds promise for hyperlipidemia research applications.
PCSK9-IN-10
🥰Excellent
Purity: 98.85%
Catalog No. T72025Cas No. 368434-98-4
PCSK9-IN-10, a potent and orally active inhibitor of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9), exhibits a half-maximal inhibitory concentration (IC50) of 6.4 µM. By enhancing the expression of Low-Density Lipoprotein Receptor (LDLR) protein and reducing PCSK9 expression, PCSK9-IN-10 effectively decreases atherosclerosis progression. This compound holds promise for hyperlipidemia research applications.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 2 mg | $35 | In Stock | |
| 5 mg | $58 | In Stock | |
| 10 mg | $93 | In Stock | |
| 25 mg | $188 | In Stock | |
| 50 mg | $296 | In Stock | |
| 100 mg | $435 | In Stock | |
| 200 mg | $616 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $59 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "PCSK9-IN-10"
Benzamidine hydrochloride
Benzamidine HCl
T83621670-14-0
Benzamidine hydrochloride (Benzamidine HCl) is a reversible inhibitor of serine proteases, including trypsin, plasmin, and thrombin (Ki of 35, 350, and 220 μM, respectively).
- $40
Size
QTY
Camostat mesylate
Cited
FOY-S980, FOY305, Camostat mesilate
T239159721-29-8
Camostat mesylate (FOY-S980) is a trypsin-like protease inhibitor and inhibits airway epithelial sodium channel (ENaC) function.
- $43
Size
QTY
CitedNafamostat mesylate Cited
FUT-175
T239282956-11-4
Nafamostat mesylate (FUT-175), a synthetic serine protease inhibitor, has been used for the treatment of allergic disorders such as asthma, allergic rhinitis and atopic dermatitis.
- $39
Size
QTY
CitedFOY 251
T867671079-09-9
FOY 251 is a proteinase inhibitor, and is an anti-proteolytic active metabolite camostate.
- $49
Size
QTY
Cetraxate hydrochloride
DV-1006, DV1006, DV 1006, Cetraxate HCl
T1976327724-96-5
Cetraxate hydrochloride (DV10062) is an oral gastrointestinal medication. It has a cytoprotective effect.
- $40
Size
QTY
Fasudil hydrochloride Cited
HA-1077 hydrochloride, Fasudil HCl, Fasudil (HA-1077) HCl, AT-877 hydrochloride
T3060105628-07-7
Fasudil hydrochloride (HA-1077) is a potent inhibitor of ROCK1, PKA, PKC, and MLCK with Ki of 0.33 μM, 1.0 μM, 9.3 μM and 55 μM, respectively.
- $35
Size
QTY
CitedFasudil
HA-1077, AT877
T1606103745-39-7
Fasudil (HA-1077) is a potent inhibitor of ROCK1, PKA, PKC, and MLCK.
- $33
Size
QTY
Chymotrypsin
Chymotrypsin A
T735949004-07-3
Chymotrypsin (Chymotrypsin A) is a serine protease synthesized by the pancreas, which cleaves protein chains on the carboxyl side of aromatic amino acids.
- $29
Size
QTY
BMT-124110 Formate
BMT-124110 Formate（1679371-59-5 Free base）
T10572LIn house
BMT-124110 Formate is a selective AAK1 inhibitor (IC50: 0.9 nM) with anti-injury sensory activity.BMT-124110 Formate inhibits the BMP-2-inducible protein kinase BIKE with an IC50: 17 nM.BMT-124110 Formate inhibits the cell-cycle protein G-related BMT-124110 Formate inhibits the cell cycle protein G-associated kinase GAK with an IC50:99 nM.
- $195
Size
QTY
SRPIN340
SRPK inhibitor
T1954218156-96-8
SRPIN340 (SRPK inhibitor), a serine/arginine-rich protein kinase (SRPK)-specific inhibitor, is potent for SRPK1 (IC50 = 0.89 uM).
- $39
Size
QTY
Piceatannol Cited
trans-Piceatannol, Astringenin
T061010083-24-6
Piceatannol (Astringenin) is an anti-inflammatory, immunomodulatory and antiproliferative agent. It inhibits p56lck and syk protein tyrosine kinases and inhibits NF-κB activation and gene expression of TNF-induced. It is synthetic from the conversion of resveratrol by cytochrome P450 1B1.
- $39
Size
QTY
CitedSelect Batch
Purity:98.85%
Contact us for more batch information
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.Product Introduction
Bioactivity
Chemical Properties
| Description | PCSK9-IN-10, a potent and orally active inhibitor of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9), exhibits a half-maximal inhibitory concentration (IC50) of 6.4 µM. By enhancing the expression of Low-Density Lipoprotein Receptor (LDLR) protein and reducing PCSK9 expression, PCSK9-IN-10 effectively decreases atherosclerosis progression. This compound holds promise for hyperlipidemia research applications. |
| Targets&IC50 | PCSK9:6.4 µM |
| In vitro | PCSK9-IN-10 (0, 2.5, 5, 12.5, 25 µM ; 24 h) significantly reduces PCSK9 protein expression and increases the expression of LDL receptor (LDLR) in a dose-dependent manner.[1] |
| In vivo | PCSK9-IN-10 (30 mg/kg; oral administration; once daily for 8 weeks) reduces total cholesterol (TC) levels and atherosclerotic plaque size in ApoE KO mice.[1] |
| Molecular Weight | 373.41 |
| Formula | C18H23N5O4 |
| Cas No. | 368434-98-4 |
| Smiles | COCCNc1nc2n(C)c(=O)n(C)c(=O)c2n1Cc1cccc(OC)c1 |
| Relative Density. | 1.32 g/cm3 (Predicted) |
Storage & Solubility Information
| Storage | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 225.0 mg/mL (602.6 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy PCSK9-IN-10 | purchase PCSK9-IN-10 | PCSK9-IN-10 cost | order PCSK9-IN-10 | PCSK9-IN-10 chemical structure | PCSK9-IN-10 in vivo | PCSK9-IN-10 in vitro | PCSK9-IN-10 formula | PCSK9-IN-10 molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.